The U.S. Pharmacopeia (USP) announces the acquisition of Stratix Labs, a microbiology technology company based in Saint Paul, MN. This acquisition marks a significant milestone for USP’s portfolio, as it will expand its microbiological solutions supporting microbial contamination control with broad applications across pharmaceuticals, including biologics and compounded medications. By acquiring Stratix Labs, USP will be better equipped to help drug manufacturers, developers, and compounding entities address industry gaps in microbial contamination control strategies, mitigating the risk of contaminated products reaching patients.
Read the full article: USP Acquires Stratix Labs, Enhancing Its Microbiology Portfolio with Innovative Technology //
Source: https://www.prnewswire.com/news-releases/usp-acquires-stratix-labs-enhancing-its-microbiology-portfolio-with-innovative-technology-302281828.html